Juan-José Garcés

Has grant

Research Scholar

Sloan Kettering Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Utilizing cell-free DNA for the selection of new immune-based therapies in multiple myeloma patients

Open Date: 2026-01-01

Close Date: 2027-01-01

Articles (10)

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction.

Year:

2025

Circulating tumor cells (CTCs) have emerged as a key prognostic factor in newly diagnosed multiple myeloma (NDMM). However, it remains unclear if high CTC counts represent a mere surrogate of tumor burden or might reflect a distinct genomic or transcriptomic entity. In this study, we characterized the genomic and transcriptomic features associated with CTC burden and assessed their combined prognostic value in NDMM patients. We analyzed 540 NDMM patients from the CoMMpass dataset with available baseline CTC information and matched bone marrow transcriptomic ( n = 374) and genomic ( n = 460) sequencing data. We then validated the results on an external cohort of 135 NDMM patients with CTCs enumerated by next‐generation flow cytometry. Higher CTC levels were significantly associated with high‐risk clinical features (e.g., ISS or IMS/IMWG 2024). Furthermore, genomic analyses revealed that high CTC counts were associated with complex genomic features such as chromothripsis, APOBEC mutagenesis, and loss of key tumor suppressors, typically linked to high‐risk disease. Transcriptomic analyses revealed that elevated CTCs were enriched in cell cycle and proliferation (PR) genes while presenting a reduced association with immune response. Importantly, CTCs also emerged as a surrogate for PR transcriptomic signatures and demonstrated prognostic superiority, potentially simplifying application in the clinical setting. Elevated CTC levels reflect aggressive biological features of multiple myeloma and outperform prognostic markers such as PR signatures. Integrating CTC data into genomic and transcriptomic classifiers could enhance risk stratification and provide a streamlined and powerful tool for clinical decision‐making in NDMM.

Year:

2025

Purpose: Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transplantation. Baseline and longitudinal measurable residual disease (MRD) negative status is a well-established positive predictive sign in Len maintenance patients. However, the clinical utility of serial MRD assessments remains uncertain, as there is no consensus on the clinical management of MRD resurgence (MRDres) or stable remissions in patients positive for MRD. Patients and Methods: In this study, we report the complete and final results of a phase II, single-arm study of 5 years of continuous Len maintenance in patients with multiple myeloma following unrestricted upfront therapy, along with exploratory peripheral blood T cell profiling experiments performed via high-dimensional spectral cytometry. Results: Patients with MRDres had inferior progression-free survival compared with those with sustained MRD negativity at the 1- and 2-year landmarks (P = 0.036, P = 0.0014, respectively); however, myeloma progression only occurred within 2 years of MRDres in 36% of patients, with no progression observed in the remaining 64% of patients at the last follow-up. Exploratory peripheral blood T cell profiling experiments throughout the trial period identified an immune signature of early relapse in patient cohorts both negative and positive for MRD at the start of maintenance therapy. T cell profiles enriched with activated cytotoxic effectors predicted early relapse, whereas quiescent T cell profiles enriched with naïve T cell populations predicted durable remissions. Conclusions: This “immune MRD” status showed predictive potential and segregated patients with MRDres and early disease progression from patients with sustained remission despite MRDres.

Year:

2025

Purpose: Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transplantation. Baseline and longitudinal measurable residual disease (MRD) negative status is a well-established positive predictive sign in Len maintenance patients. However, the clinical utility of serial MRD assessments remains uncertain, as there is no consensus on the clinical management of MRD resurgence (MRD res ) or stable remissions in patients positive for MRD. Patients and Methods: In this study, we report the complete and final results of a phase II, single-arm study of 5 years of continuous Len maintenance in patients with multiple myeloma following unrestricted upfront therapy, along with exploratory peripheral blood T cell profiling experiments performed via high-dimensional spectral cytometry. Results: Patients with MRD res had inferior progression-free survival compared with those with sustained MRD negativity at the 1- and 2-year landmarks ( P = 0.036, P = 0.0014, respectively); however, myeloma progression only occurred within 2 years of MRD res in 36% of patients, with no progression observed in the remaining 64% of patients at the last follow-up. Exploratory peripheral blood T cell profiling experiments throughout the trial period identified an immune signature of early relapse in patient cohorts both negative and positive for MRD at the start of maintenance therapy. T cell profiles enriched with activated cytotoxic effectors predicted early relapse, whereas quiescent T cell profiles enriched with naïve T cell populations predicted durable remissions. Conclusions: This “immune MRD” status showed predictive potential and segregated patients with MRD res and early disease progression from patients with sustained remission despite MRD res .

Year:

2025

Year:

2023

Year:

2023

Collaborators (23)

Esteban Braggio

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

ROSA MARIA AYALA DIAZ

Full Professor

Universidad Complutense de Madrid

SPAIN
View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Sergio Giralt

Chief Attending, Adult BMT Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Giancarlo Castellano

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Urvi Shah

Assistant Attending, Myeloma Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Roman Hajek

University of Ostrava

CZECH REPUBLIC
View details

Gunjan Shah

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Ana Alfonso-Piérola

MD, PhD

Clinica Universidad de Navarra

SPAIN
View details

Joseph Deasy

Professor of Medical Physics

Weill Cornell Medicine

UNITED STATES
View details

Jonathan Peled

Director

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mario Nuvolone

University of Pavia

ITALY
View details

Niccolò Bolli

Associate Professor

University of Milan

ITALY
View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Sridevi Rajeeve

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mattia D'Agostino

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

ITALY
View details

Anita D'Souza

Medical College of Wisconsin

UNITED STATES
View details

Ramón García-Sanz

Profesor Titular de Medicina / Hematología

Universidad Complutense de Madrid

SPAIN
View details

Hamza Hashmi

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Bruno David Lourenço Paiva

Clinica Universidad de Navarra

SPAIN
View details

Patrick Blaney

Senior Bioinformatics Programmer

NYU Langone Health

UNITED STATES
View details